Document Detail


Chemotherapy Administration: Modelling the Costs of Alternative Protocols.
MedLine Citation:
PMID:  23148697     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Background and Objective: The increasing cost of chemotherapy is placing greater pressures on limited healthcare budgets. A potentially important, but often overlooked, aspect of chemotherapy is the cost associated with administration. This study aims to develop a better understanding of these costs, and in doing so, develop a model to estimate the comparative cost of administering alternative chemotherapy protocols for economic evaluation or local decision making. Methods: We identified the potential tasks and choices related to administering intravenous chemotherapy, grouped tasks according to anticipated resource use, and allocated costs to each task using data from an evidence-based collection of cancer protocols or from primary data collection. The resources were costed from a healthcare system perspective using standard data sources within Australia. The model was applied to alternative protocols used in the treatment of three different cancers: locally advanced and metastatic non-small-cell lung cancer, adjuvant colorectal cancer and adjuvant breast cancer. Results: For the three cancer types examined, the cost of completed administration ranged from 1274 Australian dollars ($A) to $A3015 (year 2009 values) for 13 different protocols potentially used for the initial treatment of locally advanced and metastatic non-small-cell lung cancer; $A5175-8445 for seven protocols for adjuvant colorectal cancer treatment; and $A1494-4074 for seven protocols for adjuvant breast cancer treatment. Conclusions: The results are of practical significance to those undertaking economic evaluations and to decision makers who use this information within the area of chemotherapy. The examples used suggest that administration costs per visit varied inversely with the number of visits. The results provide information where little has previously been available and may allow decisions about costs and resource allocation to be made with more certainty. Although our model uses costs from the public health system within an Australian state (New South Wales), it can be adapted for use in other jurisdictions.
Authors:
Philip Haywood; Johan de Raad; Kees van Gool; Marion Haas; Gisselle Gallego; Sallie-Anne Pearson; Margaret Faedo; Robyn Ward
Related Documents :
23139207 - Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and...
6610747 - Cancer-related pain--i. prevalence in an outpatient setting as a function of stage of d...
23129377 - Optimal surgery for gastric cancer: is more always better?
22278157 - Cancer screening - united states, 2010.
17578807 - Prophylactic surgery for patients with longstanding ulcerative colitis. which option? h...
11060657 - Novel therapy for copd.
Publication Detail:
Type:  JOURNAL ARTICLE    
Journal Detail:
Title:  PharmacoEconomics     Volume:  30     ISSN:  1179-2027     ISO Abbreviation:  Pharmacoeconomics     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9212404     Medline TA:  Pharmacoeconomics     Country:  -    
Other Details:
Languages:  ENG     Pagination:  1173-1186     Citation Subset:  -    
Affiliation:
Centre for Health Economics Research and Evaluation (CHERE), University of Technology Sydney, Sydney, NSW, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Systemic thromboembolism after anti-cancer chemotherapy in a woman with ovarian germ cell tumor.
Next Document:  Estimating the Contributions of Associations and Recoding in the Implicit Association Test: The ReAL...